SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.
Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C.
Kroemer M, et al. Among authors: picard e.
Oncoimmunology. 2018 Jan 17;7(4):e1412030. doi: 10.1080/2162402X.2017.1412030. eCollection 2018.
Oncoimmunology. 2018.
PMID: 29632725
Free PMC article.
Experimental Design: A multistep approach including prediction algorithms was used to design in silico SALL4-derived peptides theoretically able to bind on common HLA-DR and HLA-A/B molecules. The presence of T-cell responses after a long term T-cell assay (28 days) agains …
Experimental Design: A multistep approach including prediction algorithms was used to design in silico SALL4-derived peptides theoretically …